

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS:	Levy, et al.	CONFIRMATION No.	8952
SERIAL No.:	10/692,764	EXAMINER:	Janet L. Epps Smith
FILING DATE:	October 24, 2003	ART UNIT:	1633
FOR:	METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA		

**VIA EFS**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached substitute for form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed concurrently with a request for continued examination.

Each item contained in this Information Disclosure statement was first cited in a corresponding Office Action for related Japanese Application No. 2004-547164, which was communicated to Applicants' U.S. attorneys on March 18, 2010. This communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement under 37 C.F.R. §1.704(d). Accordingly, no fee is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed substitute for form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Levy et al.  
U.S.S.N.: 10/692,764

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 16534-539001US.

Respectfully submitted,



Heidi A. Erlacher, Reg. No. 45,409  
Christopher E. Olson, Reg. No. 55,510  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

Address all written correspondence to

**Customer no.: 30623**

Tel: (617) 542-6000

Dated: April 2, 2010

4879382v.1